First results of the phase Ib-II #BladderGATE #ClinicalTrial : Intravenous atezolizumab + intravesical BCG upfront combination in BCG-naïve high-risk #NMIBC patients. Presented by Félix Guerrero-Ramos Department of Urology, Hospital 12 De Octubre. #EAU24 written cvoerage by Rashid K. Sayyid > bit.ly/4aKJGLf

⁦Véronique Phé⁩, a super surgeon, delivers a fantastic lecture on the increasing and important role of females in urology at #EAU24
Some of the data is shocking!
Pregnancy is not a disease!!
Mentorship is the solution!!!

Fabulous editors dinner hosted by Prof Morgan Roupret at
Automobile Club de France
#EAU24

Prostate cancer cases are expected to double from 1.4 million per year in 2020 to 2.9 million per year by 2040, new analysis suggests.

More from the Lancet Commission on #ProstateCancer in-thread 🧵

▶️ hubs.li/Q02r1b720

Meet us at the #EAU24 joint session of the European Association of Urology (EAU) European Association of Urology (EAU) and the Advanced Prostate Cancer Consensus (APCCC) this April 7th🗓️

Dive into an intensive study of advanced prostate cancer care.

Silke Gillessen and Bertrand Tombal will be steering this…

U.S. FDA FDA Oncology Pooled Analysis:
Jaleh Fallah, MD et al.
🧬This FDA analysis suggests PARPi drugs for prostate cancer work best for mutations in BRCA1, BRCA2, CDK12 & PALB2 genes.

ASCO Journal of Clinical Oncology OncoAlert Advanced Prostate Cancer Consensus Conference Prostate Cancer Foundation Toni Choueiri, MD Timil Patel, MD Jennifer Gao…

Pooled analysis by GUonc team at FDA, showing heterogenous sensitivity to PARP inhibitors across individual HRR gene mutations in mCRPC: ascopubs.org/doi/10.1200/JC…
Chana Weinstock GU Onc MD Elaine Chang Sundeep Agrawal, MD Rick Pazdur Laleh Amiri-Kordestani, MD Paul Kluetz FDA Oncology U.S. FDA Journal of Clinical Oncology ASCO

Are you a #YoungOncologist looking for personalised guidance to enhance your #CareerDevelopment ? Apply now for the ESMO Virtual Mentorship Programme to receive 1:1 mentorship to address your unmet career development needs.

📌esmo.org/career-develop…

45 is the new 50 when it comes to colorectal cancer screening!

⁦Intermountain Health⁩ ⁦Alta View Hospital⁩ #crcsm

dailyreporter.esmo.org/news/genetic-t…

Thanks to an ESMO fellowship I was able to start my career. It was also the starting point for so many colleagues.
Don’t miss this opportunity 👇🏼👇🏼.

🚀Nuevo Ensayo clínico en melanoma!!🔬 En el #Hospital12deOctubre se acaba de abrir un ensayo en primera línea con TILs para tratar el melanoma. 💪 ¡Una nueva prometedora opción! #InvestigaciónMédica #Melanoma #Hospital12deOctubre clinicaltrials.gov/study/NCT05727…

Optimizing treatment in metastatic hormone-sensitive #ProstateCancer : a case study analysis. Alicia Morgans, MD, MPH Dana-Farber joins Elena Castro in discussing the State of the Art of prostate cancer in 2024. #WatchNow on UroToday > bit.ly/3TfYETO Bayer | Pharmaceuticals

Real-world evidence informs clinical decision-making in metastatic castration-resistant #ProstateCancer . Alan H Bryce City of Hope joins Elena Castro in this discussion as part of an Independent Medical Education Initiative supported by Bayer | Pharmaceuticals > bit.ly/3uRqzzS

🔔Paper in Annals of Oncology in mCRPC patients shows that BRCA mutations (somatic and germline) result in worse outcomes than non-BRCA HRR mutations, and HRR non-BRCA mutations result in worse outcomes than non-HRR mutations

David Olmos Elena Castro #MedEd
ow.ly/mMzM50QMuI9

Agradecida a RTVE Noticias por destacar nuestro trabajo, pero también por la oportunidad de hablar del cáncer de próstata, el tumor más frecuente en varones en España pero en el que no se pone el foco lo suficiente

📢A really easy tool to estimate ctDNA fraction in the clinic, isn’t it cool??
ctdna.org
Congratulations and big thank you Alex Wyatt

Our latest on ctDNA% in mCRPC in Nature Communications: we affirm the independent strong prognostic implications & present a tool for predicting pre-blood draw whether ctDNA% is sufficiently high for genomic biomarker testing (e.g. BRCA2). Thread 👇. 1/n nature.com/articles/s4146…

🧬🧬🧬New Insights in Prostate Cancer Treatment: BRCA Mutations Impact Outcomes in Advanced Cases!
🔎Study finds identifying BRCA mutations helps predict treatment response and personalize care for aggressive prostate cancer.
#ProstateCancer #PersonalizedMedicine #Genetics …

PSMA PET imaging and targeted therapies: a case study on high-risk localized #ProstateCancer . Tian Zhang, MD, MHS @UTSWNews and Elena Castro discuss in this Independent Medical Education Initiative on UroToday > bit.ly/3IdC7Rd Bayer | Pharmaceuticals